Paul Matthias Diderichsen (Paul M Diderichsen, Paul Diderichsen)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 6

Top Topics

Multiple Myeloma

Top Venues

Clinical pharmacology and therapeutics

CPT: pharmacometrics & systems pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

John Maringwa, Paul Matthias Diderichsen, Chandni Valiathan
Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-Analysis. Clinical pharmacology and therapeutics (2024)
Jaydeep K Srimani, Paul Matthias Diderichsen, Michael J Hanley, Richard Labotka, Neeraj Gupta
Dose Titration of Ixazomib Maintenance Therapy in Transplant-Ineligible Multiple Myeloma: Exposure-Response Analysis of the TOURMALINE-MM4 Study. Clinical pharmacology and therapeutics (2023)
Michael J Hanley, Paul Matthias Diderichsen, Benjamin Rich, Anna Largajolli, Emilie Schindler, Alexander Vorog, Karthik Venkatakrishnan, Neeraj Gupta
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study. Clinical pharmacology and therapeutics (2023)
Yulia Vugmeyster, Abhigyan Ravula, Elisabeth Rouits, Paul Matthias Diderichsen, Huub Jan Kleijn, Andre Koenig, XiaoZhe Wang, Andreas Schroeder, Kosalaram Goteti, Karthik Venkatakrishnan
Model-informed selection of the recommended phase 3 dose of the inhibitor of apoptosis protein inhibitor, xevinapant, in combination with cisplatin and concurrent radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck. Clinical pharmacology and therapeutics (2023)
Neeraj Gupta, Philippe B Pierrillas, Michael J Hanley, Steven Zhang, Paul Matthias Diderichsen
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non-small cell lung cancer. CPT: pharmacometrics & systems pharmacology 11 (6) (2022)
Han Witjes, Amit Khatri, Paul Matthias Diderichsen, Jaap Mandema, Ahmed A Othman
Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. Clinical pharmacology and therapeutics 107 (2) (2019)